Shots:

• The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS
• The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%-9% vs 3% 69%); musculoskeletal pain (64%- 8% vs 25%- 2%); decreased appetite (31%- 2% vs 20%- 0%); lymphopenia (77%- 44% vs 73%- 37%); hypokalemia (21%- 8% vs 15%- 3%)
• Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) mAb used for blocking PDGFR-α and prevents receptor activation- indicated for soft tissue sarcoma (STS) in combination with doxorubicin

Ref: Eli Lilly | Image: Eli Lilly